Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2021-06-30 Regulatory Filings
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Caladrius Biosciences, Inc. It registers shares under an equity incentive compensation plan. The text includes SEC filing details, registration fee calculations, incorporation by reference of other SEC filings (10-K, 10-Q, 8-K), and legal indemnification provisions. It is a registration statement for securities issuance, not a financial report, earnings release, or management discussion. The document is not an announcement of a report but the actual registration statement itself. Form S-8 filings are related to securities registration under the Securities Act of 1933 and are classified under Regulatory Filings (RNS) as they do not fit other specific categories like capital updates or earnings releases.
2021-06-30 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 16, 2021, reporting the submission of matters to a vote of security holders at the 2021 Annual Meeting of Stockholders. It details the voting results on several proposals including director elections, auditor ratification, executive compensation advisory vote, equity plan amendment, and meeting adjournment. The content is focused on the official results of shareholder votes at the Annual Meeting. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 5158 characters, which is sufficient to contain detailed voting results rather than just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2021-06-16 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an At The Market Offering Agreement for common stock. It discusses the terms of the offering, use of proceeds, risk factors, and other details typical of a capital raising document. The presence of terms like "prospectus supplement," "offering," "sales agreement," and details about the common stock offering clearly indicate this is a capital/financing update. It is not an annual report, earnings release, or any other type of report. The document length and content confirm it is not a mere announcement but a detailed offering document. Therefore, the correct classification is Capital/Financing Update (CAP).
2021-06-04 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 4, 2021, by Caladrius Biosciences, Inc. The content describes the entry into a material definitive agreement, specifically an At The Market Offering Agreement for up to $50 million of common stock. The document includes details about the agreement, the registration statement, and legal opinions related to the offering. There are no financial statements or earnings data presented, nor is this a full annual or quarterly report. The primary focus is on the company's financing activity through a stock offering. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is 5798 characters, sufficient to contain substantive information about the financing agreement rather than a brief announcement. Hence, the classification is CAP with high confidence.
2021-06-04 English
10-Q
Interim / Quarterly Report Q1 2021
2021-05-06 English
424B2
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(2) under the Securities Act, describing a shelf registration for the issuance of up to $150 million of various securities including common stock, preferred stock, debt securities, warrants, and units. It includes detailed information about the securities, the company, risk factors, and the plan of distribution. The document is not a financial report, earnings release, or management discussion, but rather a capital raising disclosure document. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities. The document length is substantial (15,000 characters), and it is the actual prospectus, not merely an announcement of a report. Therefore, the correct classification is CAP with high confidence.
2021-05-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.